Ai Powered Radiotherapy Treatment Planning Market

According to Stratistics MRC, the Global AI-Powered Radiotherapy Treatment Planning Market is accounted for $1.8 billion in 2026 and is expected to reach $7.4 billion by 2034 growing at a CAGR of 19.4% during the forecast period. The AI-Powered Radiotherapy Treatment Planning Market encompasses intelligent software, automated contouring, dose optimization, and adaptive treatment planning technologies designed to improve precision and efficiency in radiation oncology. Increasing cancer incidence, growing demand for personalized radiotherapy, and expanding adoption of artificial intelligence in healthcare are supporting market growth. Advancements in deep learning, medical image analysis, and automated treatment planning improve clinical workflows. Growing investment in precision oncology and intelligent cancer treatment infrastructure creates additional opportunities.

Market Dynamics:

Driver:

Increasing cancer incidence and demand for precision radiotherapy treatment planning

Increasing cancer incidence and demand for precision radiotherapy treatment planning are driving market growth. Healthcare providers are adopting AI-powered treatment planning solutions to improve tumor targeting, optimize radiation dose distribution, and reduce planning time. Growing utilization of intensity-modulated radiotherapy and image-guided radiation therapy encourages investment in intelligent planning technologies. AI-based systems support automated contouring, organ-at-risk identification, and treatment plan optimization. Advancements in medical imaging and deep learning improve planning consistency. Expanding oncology infrastructure further strengthens demand for automated radiotherapy solutions.

Restraint:

High implementation costs and challenges in clinical validation of AI-based planning systems

High implementation costs and challenges in clinical validation of AI-based planning systems restrain market growth. AI-powered radiotherapy platforms require investment in specialized software, computing infrastructure, integration services, and workforce training. Healthcare institutions must validate automated contours and treatment plans to ensure clinical safety and accuracy. Differences in imaging protocols, patient populations, and treatment techniques may affect algorithm performance. Complex regulatory approval processes and limited interoperability with existing oncology systems increase implementation challenges. Smaller treatment centers may face additional financial constraints.

Opportunity:

Expansion of adaptive radiotherapy and AI-enabled personalized cancer treatment

Expansion of adaptive radiotherapy and AI-enabled personalized cancer treatment presents significant growth opportunities. Healthcare providers are investing in intelligent planning systems that adjust treatment strategies according to anatomical changes and patient-specific clinical information. AI-powered contouring, automated dose optimization, and treatment outcome prediction support more efficient personalized radiotherapy workflows. Growing integration of MRI-guided radiotherapy, cloud-based analytics, and advanced imaging technologies encourages innovation. Collaboration among oncology equipment manufacturers, software developers, and healthcare institutions is expected to accelerate adoption of intelligent treatment planning solutions.

Threat:

Algorithm reliability concerns and cybersecurity risks in AI-powered oncology systems

Algorithm reliability concerns and cybersecurity risks in AI-powered oncology systems pose significant challenges to market development. Automated radiotherapy planning depends on accurate imaging data, validated algorithms, and reliable clinical information. Incorrect segmentation or dose optimization could compromise treatment quality and patient safety if not detected during professional review. Cybersecurity vulnerabilities and data privacy concerns may affect connected oncology platforms. Differences in regulatory requirements and clinical acceptance standards can delay implementation. Increasing competition among technology providers further influences market development.

Covid-19 Impact:

The COVID-19 pandemic disrupted oncology services through hospital restrictions, delayed cancer diagnoses, and interruptions in routine radiotherapy treatment planning. Healthcare facilities experienced staffing shortages and increased pressure to maintain essential cancer care. These challenges encouraged interest in automated contouring, remote treatment planning, and digital oncology workflows. AI-powered solutions offered opportunities to reduce repetitive planning activities and support operational continuity. Post-pandemic recovery in cancer screening, treatment volumes, and investment in healthcare digitalization continues to support adoption of intelligent radiotherapy planning technologies.

The software segment is expected to be the largest during the forecast period

The software segment is expected to account for the largest market share during the forecast period due to increasing demand for automated treatment planning, AI-powered contouring, and intelligent dose optimization solutions. Software platforms process medical imaging information and clinical treatment parameters to support accurate radiation therapy planning. Growing integration with existing treatment planning systems and oncology information platforms encourages adoption. Advancements in deep learning, adaptive radiotherapy, and automated quality assurance improve software capabilities. Expanding precision oncology initiatives further strengthen segment growth.

The generative AI & foundation models segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the generative AI & foundation models segment is predicted to witness the highest growth rate due to increasing research into advanced models capable of supporting automated contouring, treatment plan generation, and clinical decision assistance. Foundation models may enable adaptation across different imaging modalities and anatomical regions. Growing investment in generative AI research and personalized oncology encourages technology development. Advancements in multimodal learning, synthetic data generation, and model validation could accelerate adoption, although clinical deployment requires rigorous safety evaluation.

Region with largest share:

During the forecast period, North America is expected to hold the largest market share due to advanced oncology infrastructure, significant healthcare technology investment, and widespread adoption of precision radiotherapy solutions. The United States and Canada are advancing AI-enabled treatment planning through research collaborations, clinical software integration, and automated oncology workflows. Growing demand for efficient cancer treatment and availability of specialized radiation oncology facilities encourage regional market development. Collaboration among medical technology companies, research institutions, and healthcare providers further strengthens North America's position.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding cancer treatment infrastructure, increasing healthcare expenditure, and growing adoption of AI-powered medical technologies. China, India, Japan, South Korea, and Australia are advancing radiation oncology modernization and intelligent treatment planning initiatives. Increasing cancer treatment demand and government-supported healthcare digitalization encourage technology investment. Improvements in medical imaging, cloud-based analytics, and AI-assisted clinical workflows are expected to accelerate regional market growth.

Key players in the market

Some of the key players in the AI-Powered Radiotherapy Treatment Planning Market include Siemens Healthineers AG (Varian), Elekta AB, RaySearch Laboratories AB, Accuray Incorporated, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Brainlab SE, MIM Software Inc., MVision AI Oy, Limbus AI, Radformation, Inc., TheraPanacea, DOSIsoft SA, Mirada Medical Ltd., Carina Medical LLC, Siris Medical, Inc., Prowess Inc., and Manteia Medical Technologies.

Key Developments:

In September 2026, RaySearch Laboratories AB announced a partnership with the International Atomic Energy Agency (IAEA) under the Rays of Hope initiative to expand access to radiotherapy in underserved regions. The collaboration supports treatment planning capabilities, clinical expertise, and broader availability of advanced radiation oncology solutions.

In September 2026, Siemens Healthineers AG (Varian) launched Accela, a radiotherapy solution incorporating advanced AI-assisted treatment planning and NeoArc dynamic modulated arc therapy. The platform is designed to optimize treatment quality and delivery speed while supporting more efficient stereotactic radiation therapy workflows.

In September 2026, Elekta AB announced expanded adaptive radiotherapy capabilities across its treatment portfolio, supported by Elekta ONE software. The developments include additional online adaptive workflows for Elekta Harmony and real-time adaptive planning for prostate brachytherapy, supporting more personalized radiation treatment.

Components Covered:
• Software
• Hardware
• Services

Solution Types Covered:
• Automated Contouring & Segmentation
• Automated Treatment Plan Generation
• AI-Based Dose Optimization
• Adaptive Radiotherapy Planning
• Treatment Plan Quality Assurance
• Organ-at-Risk Identification & Protection
• Treatment Outcome Prediction & Decision Support
• Other Solution Types

Technologies Covered:
• Machine Learning & Predictive Analytics
• Deep Learning & Neural Networks
• Computer Vision & Medical Image Analysis
• Reinforcement Learning & Automated Optimization
• Generative AI & Foundation Models
• Knowledge-Based Treatment Planning
• Cloud Computing & AI-Enabled Data Analytics
• Other Technologies

Cancer Types Covered:
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Head & Neck Cancer
• Brain & Central Nervous System Tumors
• Gastrointestinal Cancers
• Gynecological Cancers
• Other Cancer Types

End Users Covered:
• Hospitals
• Specialty Cancer Treatment Centers
• Radiation Oncology Clinics
• Academic & Research Institutions
• Other End Users

Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
 Saudi Arabia
 United Arab Emirates
 Qatar
 Israel
 Rest of Middle East
o Africa
 South Africa
 Egypt
 Morocco
 Rest of Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances